Harry J. Leonhardt
2018 - Halozyme Therapeutics
Compensation breakdown
| Non-Equity Incentive Plan | $304,218 |
|---|---|
| Option Awards | $575,009 |
| Salary | $442,000 |
| Stock Awards | $575,018 |
| Other | $11,355 |
| Total | $1,907,600 |
Leonhardt received $575K in stock awards, accounting for 30% of the total pay in 2018.
Leonhardt also received $304.2K in non-equity incentive plan, $575K in option awards, $442K in salary and $11.4K in other compensation.
Rankings
In 2018, Harry J. Leonhardt's compensation ranked 5,985th out of 14,244 executives tracked by ExecPay. In other words, Leonhardt earned more than 58.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,985 out of 14,244 | 58th |
Division Manufacturing | 2,279 out of 5,765 | 61st |
Major group Chemicals And Allied Products | 854 out of 2,128 | 60th |
Industry group Drugs | 714 out of 1,817 | 61st |
Industry Biological Products, Except Diagnostic Substances | 138 out of 339 | 59th |
Pay ratio
| Harry J. Leonhardt's Pay | $1,907,600 |
|---|---|
| Median Employee's Pay | $199,899 |
| Pay Ratio | 10to 1 |
In 2018, the annual total compensation of Harry J. Leonhardt was $1,907,600.
The annual total compensation of the median employee at Halozyme Therapeutics was $199,899.
The ratio of Harry J. Leonhardt's pay to the pay of median employee was therefore 10 to one.
Leonhardt's colleagues
We found four more compensation records of executives who worked with Harry J. Leonhardt at Halozyme Therapeutics in 2018.
News
April 26, 2023
April 27, 2022
March 20, 2020
March 22, 2019